Burke T J, Nobles E M, Wolf P S, Erickson A L
Curr Med Res Opin. 1983;8 Suppl 3:25-37. doi: 10.1185/03007998309109833.
Indapamide, a newly developed antihypertensive agent with modest diuretic properties, reduced mean arterial pressure toward normal in dogs made hypertensive with salt and DOCA, while low-dose furosemide (0.1 mg per day) and hydrochlorothiazide (1 and 50 mg per day) did not result in similar degrees of blood pressure control. Indapamide, low-dose furosemide and hydrochlorothiazide treatment all resulted in similar decreases in body weight suggesting that the antihypertensive effect of indapamide occurs through a mechanism independent of contraction of extracellular fluid volume. Intravenous indapamide at doses of 0.3, 1.0 and 3.0 mg/kg caused progressive increases in sodium, potassium and chloride excretion when urine losses were replaced by isotonic saline to prevent extracellular fluid volume contraction. Only at 3.0 mg/kg did plasma potassium decrease significantly (2.92 +/- 0.03 to 2.69 +/- 0.05 mmol/l; p less than 0.05). Neither glomerular filtration rate (GFR) nor renal blood flow (flowmeter) decreased in a dose-related manner; however, effective renal plasma flow assessed by para-aminohippurate clearance did decrease about 15% at the highest dose (p less than 0.05). Proximal re-collection micropuncture studies demonstrated decreased proximal reabsorption. Cortical diluting segment reabsorption was decreased, but CNa + CH2O/GFR increased from 7% to 11% (p less than 0.05). These results indicate that, at doses up to 3.0 mg/kg, indapamide causes a natriuresis which is modest and similar to that seen with thiazides. No decrease in GFR or renal blood flow was observed. This drug apparently exerts a natriuretic effect through an inhibition of solute reabsorption in both the proximal nephron and the cortical diluting segment.
吲达帕胺是一种新开发的具有适度利尿特性的抗高血压药物,可使用盐和去氧皮质酮诱导高血压的犬的平均动脉压降至正常水平,而低剂量呋塞米(每天0.1毫克)和氢氯噻嗪(每天1毫克和50毫克)则未产生类似程度的血压控制效果。吲达帕胺、低剂量呋塞米和氢氯噻嗪治疗均导致体重出现类似程度的下降,这表明吲达帕胺的抗高血压作用是通过一种独立于细胞外液量收缩的机制实现的。当用等渗盐水补充尿流失以防止细胞外液量收缩时,静脉注射剂量为0.3、1.0和3.0毫克/千克的吲达帕胺可使钠、钾和氯排泄量逐渐增加。仅在3.0毫克/千克时,血浆钾才显著降低(从2.92±0.03毫摩尔/升降至2.69±0.05毫摩尔/升;p<0.05)。肾小球滤过率(GFR)和肾血流量(流量计)均未呈剂量相关下降;然而,通过对氨基马尿酸清除率评估的有效肾血浆流量在最高剂量时确实下降了约15%(p<0.05)。近端重吸收微穿刺研究显示近端重吸收减少。皮质稀释段重吸收减少,但CNa + CH2O/GFR从7%增加至11%(p<0.05)。这些结果表明,在高达3.0毫克/千克的剂量下,吲达帕胺会引起适度的利钠作用,与噻嗪类药物相似。未观察到GFR或肾血流量下降。该药物显然通过抑制近端肾单位和皮质稀释段的溶质重吸收发挥利钠作用。